BRAF and metastatic melanoma: In this regard, treatment guidelines establish surgical resection as the standard of care for localized and locoregional disease (3) and Vemurafenib, a BRAF inhibitor, is approved for treatment of BRAF-mutated metastatic melanoma patients (12) that has been found to induce a positive response in ~50% of patients (30).